Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PURITAN MEDICAL

International Collaboration Finds Three New Lupus Genes

By BiotechDaily International staff writers
Posted on 11 Apr 2012
Three newly confirmed lupus genes are providing new clues into this devastating autoimmune disorder.

An article published in the April 6, 2012, issue of the American Journal of Human Genetics described three lupus genes discovered by scientists from Oklahoma Medical Research Foundation (OMRF; Oklahoma City, OK, USA). The massive international collaboration included universities and research facilities in Granada (Spain), Taipei (Taiwan), Seoul (republic of Korea), Bogota (Colombia), and across the United States, OMRF scientists collected more than 17,000 samples for large-scale genetic testing.

The project, which started in 2009, took one year to gather the samples and another year to run the genetic tests. Since then, the researchers have studied the data, according to lead author and OMRF scientist Christopher Lessard, PhD “We have pinned down three new genes that show statistical significance for lupus risk,” he said. “We’ve also turned up another 11 regions we think might be related to lupus, but those need more study.”

The study is significant for its inclusion of several ethnic groups and findings that show that the genes that cause lupus are not always universal, according to OMRF researcher Patrick Gaffney, MD Utilizing samples from a wide range of ethnic backgrounds, scientists found the genes IRF8 and TMEM39a were associated with lupus in European-American, African-American, Gullah, and Asian patients. A third gene named IKZF3 was only significant in African-American and European-American samples.

The huge undertaking has already revealed other discoveries, according to Dr. Gaffney. Up to now, the project has culminated in at least 15 published articles and several more are in the pipeline. The next step will be studying the genes to find out what role they play in lupus, according to Dr. Lessard.

“Identifying and characterizing these genetic risk factors in lupus will undoubtedly lead to improved diagnostics and therapeutics for this complex disease," said senior author and OMRF scientist Kathy Moser, PhD.

Lupus Foundation of America, Oklahoma chapter executive director Mannix Barnes noted that the finding marks another significant step for patients. “The importance of continued research for lupus is imperative to finding the cause and treatments for a disease that affects over 1.5 million Americans, mostly women,” said Dr. Barnes. “I can honestly say from an executive viewpoint in an organization that fields thousands of calls annually from women affected by this disease, I hope research one day will be able to put us out of business and start saving lives in return.”

Related Links:

Oklahoma Medical Research Foundation



Channels

Drug Discovery

view channel
Image: A new micelle delivery system for the protective polyphenols resveratrol and quercetin (mRQ) may have value in cancer chemotherapy (Photo courtesy of Oregon State University).

Micelles Containing Resveratrol and Quercetin Reverse Doxorubicin Cardiotoxicity

Cancer researchers blocked the toxic effects of the cancer drug doxorubicin (DOX) by administering it together with the plant antioxidants resveratrol and quercetin. Although in use for more than 40... Read more

Lab Technologies

view channel
Image: The Leica DM2500 LED Microscope for clinical laboratories and research applications (Photo courtesy of Leica Microsystems).

New LED Microscope Completes Line of Clinical and Research Tools

A popular microscope used for both clinical and research applications is now available with LED illumination. The Leica (Wetzlar, Germany) DM2500 and DM2500 LED microscopes represent a class of tools... Read more

Business

view channel

Teva Buys Allergan Generic Business Unit

Teva Pharmaceutical Industries (Petah Tikva, Israel) has bought the Allergan (Irvine, CA, USA) generic drugs business for USD 40.5 billion in cash and stock, solidifying its position as the world's largest generic drug maker. Under the terms of the agreement, Teva will pay USD 33.75 billion in cash and USD 6.... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.